Analysts Offer Predictions for EVAX FY2029 Earnings

Evaxion Biotech A/S (NASDAQ:EVAX) – Investment analysts at HC Wainwright issued their FY2029 EPS estimates for Evaxion Biotech A/S in a research note issued to investors on Monday, February 3rd. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per share of $0.11 for the year. HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Evaxion Biotech A/S’s current full-year earnings is ($0.43) per share.

Evaxion Biotech A/S Trading Down 2.0 %

NASDAQ EVAX opened at $2.40 on Tuesday. The firm has a 50 day simple moving average of $4.88 and a 200-day simple moving average of $10.66. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80. Evaxion Biotech A/S has a one year low of $2.22 and a one year high of $23.70.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC purchased a new position in Evaxion Biotech A/S (NASDAQ:EVAX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned about 2.98% of Evaxion Biotech A/S as of its most recent SEC filing. Institutional investors own 11.04% of the company’s stock.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.